BMEA

Biomea Fusion, Inc.

A clinical-stage biopharmaceutical company that designs oral covalent small molecule drugs to treat diabetes and obesity. Its lead candidate, icovamenib, forms a permanent bond with a protein called menin to help the body regenerate its own insulin-producing beta cells. Founded in 2017 by Thomas Butler in Redwood City, California, the name "Biomea" blends the Greek word for life ("bios") with the Latin word for "my," reflecting the mission to improve the life of each patient.